Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update
暂无分享，去创建一个
T. Klein | T. Klein | M. Pirmohamed | D. Haas | D. Kroetz | M. Wilkinson | J. Hoffman | J. Hicks | R. Freimuth | M. Martin | B. Dong | D. Kroetz | J. M. Hoffman | D. Haas | R R Freimuth | M A Martin | M. A. Martin
[1] Jacqueline Adam,et al. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity. , 2013, The Journal of allergy and clinical immunology.
[2] Kristin A. Maloney,et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.
[3] Dan M. Roden,et al. Leveraging the electronic health record to implement genomic medicine , 2012, Genetics in Medicine.
[4] J. Kelsoe,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.
[5] T. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing , 2012, Clinical pharmacology and therapeutics.
[6] D. Roden,et al. The Emerging Role of Electronic Medical Records in Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.
[7] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.